Project Details
Description
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
| Status | Active |
|---|---|
| Effective start/end date | 3/5/20 → 3/31/25 |
Funding
- SPRUCE BIOSCIENCES, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.